March 27, 2017 / 1:03 PM / in 7 months

BUZZ-Aurinia Pharmaceuticals: Kidney drug succeeds study

** Canadian drugmaker’s U.S.-listed shares up 6.6 pct at $8.55 in premarket trade

** Reports 48-week results from open-label study of its kidney drug; says data shows drug succeeded study

** The drug, voclosporin, is being developed to treat lupus nephritis, an inflammation of the kidney

** Up to Friday’s close, stock had more than doubled in the past 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below